[ad_1]
The global antimalarial drug market is expected to grow by $ 310.75 million according to Technavio. Despite the impact of the COVID-19 pandemic, growth in this market is expected to remain stable in the first half of 2020 and throughout the forecast period.
This press release has multimedia. See the full statement here: https://www.businesswire.com/news/home/20200414005657/en/
Technavio has released the latest market research report titled Global Malaria Drug Market 2020-2024 (Chart: Business Wire)
The antimalarial drug market is growing significantly with an increasing demand for antimalarial hydroxychloroquine and antibacterial azithromycin, to treat patients suffering from COVID-19, a global pandemic. These medications are given in combination with other medications according to the revised clinical guidelines. Furthermore, the persistent fight against COVID-19 is also prompting other nations such as the United States to import these anti-malaria drugs, thus contributing to market growth.
The market is driven by strong financing to eradicate malaria. In addition, the availability of improved POC biomarkers and diagnostics for malaria is anticipated to drive growth in the antimalarial drug market.
African countries such as Ethiopia, Nigeria, Ghana, and Kenya are among the most malaria-affected nations worldwide. The prevalence rate of malaria is also increasing in Cambodia and Papua New Guinea. This is mainly due to the presence of a poorly developed health system and the low level of sanitation in these regions. Furthermore, these regions have insufficient funds to maintain a healthy standard of living. This is encouraging various governmental and non-governmental organizations, such as the Bill and Melinda Gates Foundation, MMV and the World Bank, to conduct various awareness camps, which are supported by strong funds. Developed economies like the United States also fight malaria. For example, the US government. USA It invested $ 1.35 billion in the Global Fund to Fight AIDS, Tuberculosis and Malaria in fiscal year 2017, and approximately one third of the total fund will be used for malaria control and elimination programs. This is leading to an increase in the number of research and development activities for the creation of effective antimalarial drugs. The availability of solid funds to eradicate malaria is expected to drive market growth during the forecast period.
The story continues
AstraZeneca Plc operates the business in the biopharmaceuticals segment. The company offers new therapies for the treatment of various respiratory, cardiovascular and oncological indications. They offer Avloclor, which is a chloroquine tablet. This medication helps in the prevention of malaria.
Bayer AG offers products through the following business units: pharmaceuticals, crop science, consumer health and animal health. The company offers Resochin, which is a generic chloroquine tablet indicated for the treatment of malaria.
Cipla Inc. operates in various business segments, namely pharmaceuticals and startups. The company offers MEFLIAM PLUS, which is a fixed-dose combination tablet. Contains mefloquine hydrochloride and artesunate. This medication is indicated for the treatment of multidrug-resistant falciparum malaria.
F. Hoffmann-La Roche Ltd. offers products through the following business segments: Pharmaceuticals and Diagnostics. The company offers Lariam, it is a mefloquine hydrochloride prescription tablet. This tablet is used to treat malaria and acts as a blood schizonticide.
GlaxoSmithKline Plc offers products through the following business segments: pharmaceuticals, consumer healthcare and vaccines. The company offers Krintafel, which is an 8-aminoquinoline derivative. It fights against all stages of the life cycle of P. vivax, including hypnozoites.
Technavio is a world leader in research and technological advice. His research and analysis focus on emerging market trends and provide practical information to help companies identify market opportunities and develop effective strategies to optimize their market positions.
With more than 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Its customer base consists of companies of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research and market insights to identify opportunities in existing markets and potentials and assess their competitive positions within changing market scenarios.
See the source version at businesswire.com: https://www.businesswire.com/news/home/20200414005657/en/“data-reactid =” 69 “>See the source version at businesswire.com: https://www.businesswire.com/news/home/20200414005657/en/
